Summary from GEO: "Current research on CDK4/6 inhibitors (CDK4/6i) in the pre-clinical and clinical spaces are largely concerned with gaining a deeper understanding of how these drugs delay tumor growth, and how to prevent cancer cell resistance. By coordinating a first-in-kind phase II clinical trial of the CDK4/6i abemaciclib for patients with progressive dedifferentiated liposarcoma (DDLS) with...

This dataset contains genomic profile samples, mutation information, and sequencing data from 218 prostate tumors, including 181 primaries and 37 metastases, and 14 prostate cancer cell lines and xenografts. After generating a map of CNAs across the dataset, the authors of this study used matching mRNA and microRNA transcriptome and exon resequencing data to define the frequency of alterations in...